Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Derosa

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Future Oncology (London, England)|October 6, 2015
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluationSergio Bracarda, Claudia Caserta, Luca Galli, et al.
Expert Review of Clinical Immunology|June 24, 2024
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implicationsMarco Sposito, Serena Eccher, Luca Pasqualin, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 29, 2022
Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinomaEmeline Colomba, Carolina Alves Costa Silva, Gwénaël Le Teuff, et al.
Molecular Diagnosis & Therapy|March 30, 2016
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Emanuela Scarpi, et al.
Oncotarget|September 5, 2015
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patientsAnna Solini, Vittorio Simeon, Lisa Derosa, et al.
Oncoimmunology|July 3, 2024
<i>Faecalibaterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitorsMarius Bredon, Camille Danne, Hang Phuong Pham, et al.
Plos One|July 20, 2016
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Robert J Jones, et al.
Oncotarget|July 14, 2016
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinibCristian Lolli, Umberto Basso, Lisa Derosa, et al.
Investigational New Drugs|August 26, 2016
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patientsTeresa Di Desidero, Lisa Derosa, Luca Galli, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Future Oncology (London, England)|October 6, 2015
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluationSergio Bracarda, Claudia Caserta, Luca Galli, et al.
Expert Review of Clinical Immunology|June 24, 2024
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implicationsMarco Sposito, Serena Eccher, Luca Pasqualin, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 29, 2022
Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinomaEmeline Colomba, Carolina Alves Costa Silva, Gwénaël Le Teuff, et al.
Molecular Diagnosis & Therapy|March 30, 2016
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Emanuela Scarpi, et al.
Oncotarget|September 5, 2015
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patientsAnna Solini, Vittorio Simeon, Lisa Derosa, et al.
Oncoimmunology|July 3, 2024
<i>Faecalibaterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitorsMarius Bredon, Camille Danne, Hang Phuong Pham, et al.
Plos One|July 20, 2016
Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate CancerVincenza Conteduca, Simon J Crabb, Robert J Jones, et al.
Oncotarget|July 14, 2016
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinibCristian Lolli, Umberto Basso, Lisa Derosa, et al.
Investigational New Drugs|August 26, 2016
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patientsTeresa Di Desidero, Lisa Derosa, Luca Galli, et al.
Pageof 11